Lond

The American Diabetes Association Announces the 2024 National Scientific and Health Care Achievement Award Winners

Retrieved on: 
Mercoledì, Marzo 6, 2024
Reward, Bachelor of Science, Nursing, Royal College of Pathologists, Doctor of Philosophy, Pregnancy, University, FRCP, CUPS, Social media, American Diabetes Association, Doctor of Science, MB, FESC, Lois Jovanovic, FACP, FACE, FACC, MRCP, Book, Physician, Female, Doctor of Pharmacy, Life, Learning, Prognosis, Prediabetes, Insulin resistance, Lond, Research, FAHA, Interest, Patient, Causality, Public

ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.

Key Points: 
  • ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.
  • The awards honor academics, health care providers, and educators who have contributed to substantial advances in diabetes care and research.
  • ), FMedSci is the recipient of the 2024 Banting Medal for Scientific Achievement, which recognizes significant long-term contributions to the understanding, treatment, or prevention of diabetes.
  • Parker, PhD is the recipient of the 2024 Outstanding Scientific Achievement Award, which recognizes research in diabetes that demonstrates particular independence of thought and originality.

Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers

Safety, AML, Intelligence, Cancer, Interleukin 2, CA4P, DIPG, Private Securities Litigation Reform Act, Therapy, Form 10-K, Colorectal cancer, Cocaine, Acute respiratory distress syndrome, Kawasaki, CEO, Immune system, RNA, Glioma, Virology, Pointr, Food, Risk, Trial of the century, Severe acute respiratory syndrome coronavirus 2, CA, Trial, COVID-19, Treatment, Immunotherapy, Oxigen Services, Food and Drug Administration Amendments Act of 2007, Diffuse intrinsic pontine glioma, Forward-looking statement, Optimism, Annual report, Acquisition, Company, GLOBE, The Trial, SEC, Lond, Communication, Survival, Pancreatic cancer, Patient, Kawasaki disease, Melanoma, Glioblastoma, New, Pharmaceutical industry

The 140 mg/m2 dose was shown to be the optimal dose for OT-101 in the prior trial targeting pancreatic cancer, melanoma, and colorectal cancer (P001).

Key Points: 
  • The 140 mg/m2 dose was shown to be the optimal dose for OT-101 in the prior trial targeting pancreatic cancer, melanoma, and colorectal cancer (P001).
  • Therefore, the Company believes that increasing the dose above 140 mg/m2 should further enhance the clinical activity of OT-101.
  • We are excited to see this clear demonstration of safety for the OT-101/IL-2 combination, noted Dr. Vuong Trieu, CEO of Oncotelic.
  • Our analysis to date suggests that the OT-101/IL-2 combination could further improve the cure rate of these cancers.